"Because you already know that it could merge and become one... and trade in the US. If not mistaken, the only filing that is to be filed is a 10Q... but that should be easy since it takes care of the BK months"
As PwC CLEARLY outlines in their reports, NOBODY was interested in purchasing the company or its equity. The SISP was UNSUCCESSFUL.
The ONLY transaction that drew interest was for the Assets of BioAmber Inc.
As for LCY Bio to "go public", there are plenty of options available to do that. A reverse merger into a US ticker is one option. The going rate for a fully reporting ticker with no debt is about $250K-$400K depending on how "seasoned" it is. They could also do an S-1 or S-3.
If they choose to RM into BIOAQ, assuming FINRA would even process such a transaction they would then HAVE to take on the debt....and even if they did that the $250K or so would end up in the US creditors hands...namely Mitsui.
Why would they do that?
There is nothing in BioAmber Inc. they could want, they already will have the operating assets. And as we see via the PwC reports, NOBODY wanted the company...only its assets, namely the Sarnia plant.
There is no amount of wishful thinking that will change that.
"Harsh reality is always better than false hope"
